IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in this application.

1-4. (Cancelled)

5. (Withdrawn) A method of treating a subject with a cancer, the method comprising administering to the subject an inhibitor of indoleamine-2,3-dioxygenase in an amount effective to reverse indoleamione-2,3-dioxygenase-mediated immunosuppression, and administering at least one additional therapeutic agent, wherein the administration of the inhibitor of indoleamine-2,3-dioxygenase and the at least one additional therapeutic agent demonstrate therapeutic synergy, wherein at least one additional therapeutic agent is radiation therapy, and wherein the inhibitor of indoleamine-2,3-dioxygenase is selected from the group consisting of 1-methyl-tryptophan, β-(3-benzofuranyl)-alanine, β-(3-benzo(b)thienyl)-alanine, and 6-nitro-D-tryptophan.

6. (Withdrawn) The method of claim 5 wherein the radiation therapy is localized radiation therapy delivered to the tumor.

7. (Withdrawn) The method of claim 5 wherein the radiation therapy is total body irradiation.

8. (Cancelled)

9. (Cancelled)

10. (Withdrawn) The method of claim 5 wherein the inhibitor of indoleamine-2,3-dioxygenase is 1-methyl-tryptophan.

11. (Cancelled)

12. (Withdrawn) The method of claim 5 wherein the inhibitor of indoleamine-2,3-dioxygenase is selected from the group consisting of the D isomer of 1-methyl-tryptophan, the D isomer of β-(3-benzofuranyl)-alanine, the D isomer of β-(3-benzo(b)thienyl)-alanine, and the D isomer of 6-nitro-D-tryptophan.

13-34. (Cancelled)

35. (Withdrawn) A method augmenting rejection of tumor cells in a subject, the method comprsising administering an inhibitor of indoleamine-2,3-dioxygenase selected from the group consisting of 1-methyl-tryptophan, β-(3-benzofuranyl)-alanine, β-(3-benzo(b)thienyl)-alanine, and 6-nitro-D-tryptophan and administering radiation therapy, wherein the rejection of tumor cells obtained by administering both the inhibitor of indoleamine-2,3-dioxygenase and the radiation therapy is greater than that obtained by administering either the inhibitor of indoleamine-2,3-dioxygenase or the radiation therapy alone.

36. (Withdrawn) A method of treating cancer, the method comprising administering an inhibitor of indoleamine-2,3-dioxygenase selected from the group consisting of 1-methyl-tryptophan, β-(3-benzofuranyl)-alanine, β-(3-benzo(b)thienyl)-alanine, and 6-nitro-D-tryptophan and administering radiation therapy, wherein the cancer survivial rate observed by administering both the inhibitor of indoleamine-2,3-dioxygenase and the radiation therapy is greater than the cancer survival rate observed by administering either the inhibitor of indoleamine-2,3-dioxygenase or the radiation therapy alone.

37. (Withdrawn) A method of reducing tumor size or tumor growth in a subject, the method comprising administering an inhibitor of indoleamine-2,3-dioxygenase selected from the group consisting of 1-methyl-tryptophan, β-(3-benzofuranyl)-alanine, β-(3-benzo(b)thienyl)-alanine, and 6-nitro-D-tryptophan and administering radiation therapy, wherein the tumor size or tumor growth observed with the administration of both the inhibitor of indoleamine-2,3-dioxygenase and the radiation therapy is less than the tumor size or tumor growth observed by administering either the inhibitor of indoleamine-2,3-dioxygenase or the radiation therapy alone.

38. (Withdrawn) The method of claim 5, wherein the indoleamine-2,3-dioxygenase-mediated immunosuppression is mediated by an antigen presenting cell (APC).

39. (Withdrawn) The method of claim 5, wherein the cancer is selected from the group consisting of melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumors, lymphoma, sarcoma, ovarian cancer and Kaposi's sarcoma.

40-43. (Cancelled)

44. (Currently Amended) A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition consisting essentially of 1-methyl-D-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.

45. (Cancelled)

46. (Cancelled)

47. (Currently Amended) A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition comprising 1-methyl-D-tryptophan, but not 1-methyl-L-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.

48. (Cancelled)

49. (Currently Amended) A method of reducing tumor size or slowing tumor growth in a subject, the method comprising administering to the subject a pharmaceutical composition consisting essentially of 1-methyl-D-tryptophan, wherein said composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.

50. (Cancelled)

51. (Cancelled)

52. (Currently Amended) A method of reducing tumor size or slowing tumor growth in a subject, the method comprising administering to the subject a pharmaceutical composition comprising 1-methyl-D-tryptophan, but not 1-methyl-L-tryptophan, wherein the pharmaceutical composition is administered before, during, or after at least one cytotoxic antineoplastic chemotherapeutic agent.

53. (Cancelled)

54. (Currently Amended) The method of claim ~~45 or 50~~ 44, 47, 49 or 52, wherein the antineoplastic chemotherapeutic agent is selected from the group consisting of: cyclophosphamide, methotrexate, fluorouracil, doxorubicin, vincristine, ifosfamide, cisplatin, gemcytabine, busulfan, and ara-C.

55. (Currently Amended) The method of claim 44, ~~46 or~~ 47, 49 or 52 wherein the cancer is selected from the group consisting of melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumors, lymphoma, sarcoma, ovarian cancer, Kaposi's sarcoma, Hodgkin's Disease, mutiple myeloma, neuroblastoma, stomach cancer, cervical cancer, endometrial cancer, testicular cancer, thyroid cancer, esophageal cancer, genitourinary tract cancer, premalignant skin lesions, and adrenal cortical cancer.

56. (Cancelled)

57. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52 further comprising administering a cytokine.

58. (Previously Presented) The method of claim 57 wherein the cytokine is granulocyte macrophage colony stimulating factor (GM-CSF) or its flt3-ligand.

59. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52 wherein the composition further comprises a pharmaceutically acceptable carrier.

60. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51,]] or 52 wherein the composition is formulated for oral, rectal, nasal, topical, transdermal, aerosol, buccal, sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, enteral, intraperitoneal, or intravesicular administration.

61. (Previously Presented) The method of claim 60, wherein the composition is formulated for oral delivery.

62. (Previously Presented) The method of claim 61 wherein the composition is formulated as a tablet or a capsule.

63. (Previously Presented) The method of claim 60, wherein the composition is formulated for a controlled or sustained release.

64. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52 wherein the composition is formulated as an ointment, gel, solution, patch or implant.

65. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52, wherein the composition further comprises one or more diluents, buffers, binders, disintegrants, surface active agents, thickeners, lubricants, or preservatives.

66. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52, wherein the administration is carried out in a number of doses at intervals of time.

67. (Currently Amended) The method of claim 44, [[46,]] 47, 49, [[51]] or 52, further comprising ~~wherein the composition is administered before, during or after~~ surgical resection, radiation therapy, chemotherapy, hormone therapy, anti-tumor vaccination, antibody based therapy, cytokine based therapy, whole body irradiation, bone marrow transplantation, and peripheral stem cell transplantation.

68. (Cancelled)

69. (Cancelled)